Literature DB >> 11799172

Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation.

Stephan Menne1, Carol A Roneker, Michael Roggendorf, John L Gerin, Paul J Cote, Bud C Tennant.   

Abstract

In vitro proliferation of peripheral blood mononuclear cells was used to measure virus-specific cell-mediated immunity (vCMI) following neonatal woodchuck hepatitis virus (WHV) infection. Fifteen neonates were inoculated with the W8 strain of WHV. In 11, infection was resolved, and 4 became chronic carriers. Nineteen neonates were inoculated with the W7 strain and all became chronic carriers. Seven age-matched uninfected woodchucks served as controls. Virologic and vCMI profiles among the W8 and W7 infections were compared and related to the outcome of infection. Resolving woodchucks had robust, acute-phase vCMI to WHV antigens (core, surface, and x) and to several nonoverlapping core peptides. The acute-phase vCMI was associated temporally with the clearance of viral DNA and of surface antigen from serum at 14 to 22 weeks postinfection. In contrast, in approximately half of the W8 and W7 infections that progressed to chronicity, no significant acute-phase vCMI was detected. In the remaining carriers, acute-phase vCMI was observed, but it was less frequent and incomplete compared to that of resolved woodchucks. Serum viral load developed less rapidly in those carriers that had evidence of acute-phase vCMI, but it was still increased compared to that of resolving woodchucks. Thus, vigorous and multispecific acute-phase vCMI was associated with resolution of neonatal WHV infection. Absent or incomplete acute-phase vCMI was associated with the progression to chronic infection. By analogy, these results suggest that the onset of chronic hepatitis B virus (HBV) infection in humans may be associated with deficiencies in the primary T-cell response to acute HBV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799172      PMCID: PMC135887          DOI: 10.1128/jvi.76.4.1769-1780.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks)

Authors:  S Menne; B C Tennant
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

2.  The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence.

Authors:  D R Milich; M K Chen; J L Hughes; J E Jones
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

3.  Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections.

Authors:  J T Guo; H Zhou; C Liu; C Aldrich; J Saputelli; T Whitaker; M I Barrasa; W S Mason; C Seeger
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection.

Authors:  P J Cote; B E Korba; R H Miller; J R Jacob; B H Baldwin; W E Hornbuckle; R H Purcell; B C Tennant; J L Gerin
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

5.  Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro.

Authors:  H M Diepolder; M C Jung; E Wierenga; R M Hoffmann; R Zachoval; T J Gerlach; S Scholz; G Heavner; G Riethmüller; G R Pape
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 6.  Viral mutations, TCR antagonism and escape from the immune response.

Authors:  A Franco; C Ferrari; A Sette; F V Chisari
Journal:  Curr Opin Immunol       Date:  1995-08       Impact factor: 7.486

7.  Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope.

Authors:  S Menne; J Maschke; T K Tolle; M Lu; M Roggendorf
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Hepatic expression of the woodchuck hepatitis virus X-antigen during acute and chronic infection and detection of a woodchuck hepatitis virus X-antigen antibody response.

Authors:  J R Jacob; M A Ascenzi; C A Roneker; I A Toshkov; P J Cote; J L Gerin; B C Tennant
Journal:  Hepatology       Date:  1997-12       Impact factor: 17.425

9.  HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B.

Authors:  J Vingerhoets; P Michielsen; G Vanham; E Bosmans; W Paulij; A Ramon; P Pelckmans; L Kestens; G Leroux-Roels
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

10.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

Authors:  B Rehermann; C Ferrari; C Pasquinelli; F V Chisari
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

View more
  26 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.

Authors:  Jean-Noel Billaud; Darrell Peterson; Byung O Lee; Toshiyuki Maruyama; Antony Chen; Matti Sallberg; Fermin Garduño; Phillip Goldstein; Janice Hughes; Joyce Jones; David Milich
Journal:  Vaccine       Date:  2006-11-17       Impact factor: 3.641

Review 3.  The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.

Authors:  Michael Roggendorf; Anna D Kosinska; Jia Liu; Mengji Lu
Journal:  Cold Spring Harb Perspect Med       Date:  2015-10-28       Impact factor: 6.915

4.  KIR : HLA association with clinical manifestations of HBV infection in Madurai, south India.

Authors:  Narayanan Kalyanaraman; Lakshmikanthan Thayumanavan; Mariakuttikan Jayalakshmi
Journal:  J Genet       Date:  2016-03       Impact factor: 1.166

5.  Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.

Authors:  Pamela A Norton; Stephan Menne; Gomathinayagam Sinnathamby; Lucy Betesh; Paul J Cote; Ramila Philip; Anand S Mehta; Bud C Tennant; Timothy M Block
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

6.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection.

Authors:  Dieter Glebe; Heike Lorenz; Wolfram H Gerlich; Scott D Butler; Ilia A Tochkov; Bud C Tennant; Paul Cote; Stephan Menne
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

8.  Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide.

Authors:  Ina Frank; Claudia Budde; Melanie Fiedler; Uta Dahmen; Sergei Viazov; Mengji Lu; Ulf Dittmer; Michael Roggendorf
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

9.  Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus.

Authors:  Clifford S Guy; Patricia M Mulrooney-Cousins; Norma D Churchill; Tomasz I Michalak
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

10.  Aberrant lymphocyte activation precedes delayed virus-specific T-cell response after both primary infection and secondary exposure to hepadnavirus in the woodchuck model of hepatitis B virus infection.

Authors:  Shashi A Gujar; Adam K Jenkins; Clifford S Guy; Jinguo Wang; Tomasz I Michalak
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.